Close Menu

NEW YORK (360Dx) – The US interferon-gamma release assay (IGRA) tuberculosis testing market has been largely dominated by one player, but Quest Diagnostics' acquisition of the US operations of a smaller contender has potential to increase competition in the rapidly growing market, some experts say.

The leading IGRA tuberculosis test, Qiagen's QuantiFERON-TB had global sales of $185 million in 2017, about half of which was made up of US sales, according to a spokesman.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.